What is the current market size?

The Transthyretin Amyloidosis (ATTR) market size was valued at USD 1.2 billion in 2023, driven by approvals of innovative therapies like siRNA and antisense oligonucleotides.

What is the expected growth rate?

The ATTR market is projected to grow at a CAGR of 6.8% from 2024 to 2032, fueled by rising incidence and advancements in targeted treatments.

What are the key drivers of market growth?

Key drivers include increasing prevalence of hereditary and wild-type ATTR, adoption of non-invasive diagnostics, and rising R&D investments in gene therapies.

What challenges does the market face?

High treatment costs, limited patient access in low-income regions, and regulatory hurdles for orphan drug approvals pose significant challenges.

Which regions lead the market?

North America dominates the ATTR market (58% share) due to advanced healthcare infrastructure, followed by Europe and emerging markets like Japan.

Who are the top companies in this space?

Leading players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and F. Hoffmann-La Roche, with emerging firms like Takeda expanding their portfolios.

What future opportunities exist?

Future growth opportunities lie in expanding access to therapies in Asia-Pacific, developing oral formulations, and leveraging digital health for patient monitoring.

How is technology impacting the market?

RNAi therapies and CRISPR-based gene editing are revolutionizing treatment, while AI-driven diagnostics improve early detection and disease stratification.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize orphan drug designations, accelerating approvals for ATTR therapies and encouraging innovation.

Transthyretin Amyloidosis (ATTR) - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Transthyretin Amyloidosis (ATTR) by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), by Types (Hereditary ATTR (HATTR), Wild-Type (WT) ATTR), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Transthyretin Amyloidosis (ATTR) Market Size | CAGR 12.5 Forecast 2033

Transthyretin Amyloidosis (ATTR) - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transthyretin Amyloidosis (ATTR) Market Overview

Transthyretin Amyloidosis (ATTR) is a rare, progressive disease caused by misfolded transthyretin (TTR) protein, leading to amyloid deposition in organs. The global ATTR market size was valued at $1.5 billion in 2025, driven by rising prevalence of hereditary and wild-type forms, and advancements in diagnostics. The growth outlook for the ATTR market remains robust, with a forecasted 8.5% CAGR through 2033, supported by pipeline innovation and payer coverage expansions. Key industry expansion catalysts include FDA-designated breakthrough therapies, rising awareness among clinicians, and growing adoption of disease-modifying treatments.

Loading chart…

North America dominates the market at 55% share in 2025 due to high disease awareness and reimbursement accessibility, while the Asia-Pacific region is projected to exhibit the fastest growth _(__9.2% CAGR_)_ through 2033, fueled by expanding healthcare infrastructure and diagnostic capabilities. Key forces shaping the industry include regulatory tailwinds (e.g., FDA’s accelerated approval pathway), technological breakthroughs in RNAi therapies (e.g., inclisiran), and increasing patient advocacy efforts. The market remains highly competitive, with pharma giants and biotech firms vying to capture segments through differentiated product profiles and strategic partnerships.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Alnylam Pharmaceuticals; Ionis Pharmaceuticals; Corino Therapeutics; Proclara Bioscience; Arcturus Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising Prevalence of ATTR and Diagnostic Advancements _The global Transthyretin Amyloidosis (ATTR) market is expanding due to increased awareness and adoption of next-generation sequencing (NGS) technologies, enabling earlier diagnosis of hereditary ATTR, while improved screening protocols for wild-type ATTR in elderly populations are broadening the patient pool._

Pipeline Innovation and Regulatory Tailwinds Novel therapies, including TTR gene silencers and monoclonal antibodies, are accelerating through late-stage clinical trials, supported by FDA and EMA fast-track designations. These advancements are projected to drive the Transthyretin Amyloidosis (ATTR) market size to exceed $3.2 billion by 2030, per current growth forecast models.

Restraints2 items

High Treatment Costs and Reimbursement Gaps Orphan drug pricing models, with therapies exceeding $300,000 annually, strain healthcare budgets, particularly in emerging markets. Limited reimbursement frameworks in regions like Latin America and Southeast Asia further restrict patient access.

Diagnostic Complexity and Physician Awareness Gaps ATTR’s nonspecific symptoms and overlap with other cardiomyopathies lead to delayed diagnosis. Only 30–40% of eligible patients receive a correct diagnosis within five years of symptom onset, per recent clinical studies.

Opportunities2 items

Expansion into Underserved Wild-Type ATTR Markets With aging populations driving wild-type ATTR incidence, pharma companies are prioritizing cardiovascular-focused marketing strategies. This segment is expected to account for 60% of the Transthyretin Amyloidosis (ATTR) market by 2030.

Strategic Collaborations for Real-World Evidence Generation Partnerships between biotech firms and academic institutions are leveraging digital health platforms to collect real-world evidence (RWE), addressing gaps in long-term safety data and supporting value-based pricing negotiations.

Challenges2 items

Regulatory Divergence in Global Market Access Varying approval timelines and label differences across the FDA, EMA, and PMDA complicate commercialization. For instance, patisiran received FDA approval in 2018 but only entered Japan in 2020 due to differing evidentiary requirements.

Supply Chain Vulnerabilities for Specialty Therapies Cold-chain logistics for subcutaneous gene therapies and limited manufacturing capacity pose risks to supply continuity, especially in high-income markets where demand is surging.

Market Segmentation

Loading chart…

In Transthyretin Amyloidosis (ATTR) segmentation, the application category is divided into cardiomyopathy and neuronal amyloidosis. Cardiac amyloidosis, driven by transthyretin protein accumulation in the heart, accounts for the largest market share due to its association with high morbidity and mortality. Neuronal amyloidosis, affecting peripheral nerves, contributes to a smaller but growing segment, fueled by advancements in diagnostic tools and targeted therapies. These applications influence market dynamics through differing treatment protocols and patient prevalence rates, with cardiomyopathy dominating due to its systemic impact.

The types segment in Transthyretin Amyloidosis (ATTR) market taxonomy includes wild-type (wtATTR) and variant (VATTR) subtypes. wtATTR, linked to aging and sporadic protein misfolding, represents a larger market share due to its higher prevalence in older populations. VATTR, caused by genetic mutations, remains a niche but high-growth segment, driven by genetic screening initiatives and orphan drug development. This differentiation shapes market strategies, with wtATTR emphasizing symptomatic management and VATTR focusing on gene-targeted therapies.

Transthyretin Amyloidosis (ATTR) Segmentation Breakdown7 items

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Types

Hereditary ATTR (HATTR)

Wild-Type (WT) ATTR

Regional Insights

Loading chart…

The Transthyretin Amyloidosis (ATTR) market growth is led by North America, accounting for the largest regional share. Advanced diagnostic infrastructure, robust R&D investments, and high adoption of novel therapies such as TTR stabilizers and RNAi treatments drive this dominance. Europe follows closely, supported by favorable reimbursement policies and collaborative initiatives among pharmaceutical companies and regulators. The Asia Pacific region is the fastest-growing, fueled by rising awareness, expanding healthcare access, and a growing prevalence of age-related diseases.

Key Drivers by Region5 items

North America: High patient adoption of advanced therapies, strong biotech ecosystem, and government incentives for orphan drug development.

Europe: Harmonized regulatory frameworks (e.g., EMA guidelines), cross-border clinical trials, and public-private partnerships accelerating drug commercialization.

Asia Pacific: Rising geriatric population, improving healthcare infrastructure, and increased investments in rare disease research.

Latin America: Gradual market penetration of global pharma players, supported by emerging economies like Brazil and Mexico.

Middle East & Africa: Incremental growth due to rising diagnostic capacity and partnerships with international NGOs.

The global ATTR market regional forecast highlights North America's 40% share, followed by Europe at 30%. Asia Pacific is projected to capture 20% by 2030, reflecting its untapped potential. Latin America and Middle East & Africa collectively account for 10%, with slower but steady growth driven by localized policy reforms and ecosystem maturity.

Competitive Landscape

The Transthyretin Amyloidosis (ATTR) competitive landscape is moderately consolidated, with a mix of global biopharma firms and specialized biotech entities. Key players leverage product innovation, regulatory approvals, and strategic partnerships to differentiate in a niche but high-growth market. Pricing strategies remain influenced by drug class (e.g., RNAi therapeutics vs. small molecules), while distribution channels prioritize specialty pharmacies and hospital networks. Global players dominate due to the disease’s rarity and the need for advanced R&D capabilities, though regional firms maintain relevance through localized clinical trials and patient access programs.

Competitive differentiation hinges on proprietary technology platforms (e.g., Alnylam’s RNAi, Ionis’ antisense nucleotides) and pipeline depth, with companies prioritizing Phase III trials to secure first-mover advantage. Strategic partnerships and M&A activity are prevalent to offset high R&D costs and regulatory risks. A key challenge is managing supply chain volatility for complex therapies, compounded by stringent compliance requirements. Cost containment pressures from payors further constrain margin expansion, particularly for newer high-priced treatments.

Pfizer: Innovation pipeline focused on small-molecule TTR stabilizers

Alnylam Pharmaceuticals: Partnerships leveraging RNAi technology for subcutaneous formulations

Ionis Pharmaceuticals: Collaborations with Akcea to expand antisense therapy access

Corino Therapeutics: Product launches targeting cardiac ATTR with novel siRNA candidates

Proclara Bioscience: Clinical trial expansion to address diagnostic and therapeutic gaps

Arcturus Therapeutics: Local manufacturing to reduce supply chain risks for mRNA therapies

Key Transthyretin Amyloidosis (ATTR) Companies6 items

Pfizer

Alnylam Pharmaceuticals

Ionis Pharmaceuticals

Corino Therapeutics

Proclara Bioscience

Arcturus Therapeutics

Market Ecosystem

The Transthyretin Amyloidosis (ATTR) ecosystem spans upstream technology and raw material suppliers, midstream biopharmaceutical developers and contract manufacturers, and downstream healthcare providers and payors. Value is created through innovation in disease-modifying therapies, diagnostic advancements, and patient access programs, with capture occurring via product sales, service agreements, and reimbursement models.

Biopharmaceutical companies — develop and commercialize ATTR-targeted therapies and diagnostics

Contract manufacturing organizations (CMOs) — produce drug substances and final formulations under regulatory standards

Regulatory agencies — establish approval pathways and monitor safety compliance for therapies

Healthcare providers — diagnose patients and administer treatments in clinical settings

Patient advocacy groups — drive awareness and support clinical trial recruitment

Diagnostic technology firms — supply tools for early detection and disease monitoring

Payors and insurers — determine coverage policies and reimbursement rates for treatments

Control points reside with biopharmaceutical firms and regulators, which influence therapy adoption through clinical evidence and approval timelines. Dependency risks include CMO capacity constraints and diagnostic tool standardization. High switching costs for payors due to long-term treatment regimens and partnerships between developers and providers shape interoperability requirements. Regional differences emerge in regulatory rigor and reimbursement frameworks, particularly between the United States, Europe, and emerging markets.

Recent Industry Insights

The Transthyretin Amyloidosis (ATTR) industry trends over the past 18 months reflect a dynamic landscape driven by therapeutic advancements and strategic collaborations. Key partnerships, such as Akcea Therapeutics and Ionis Pharmaceuticals expanding their _innovative oligonucleotide therapies_, have accelerated the development of disease-modifying treatments. In M&A activity, Alnylam Pharmaceuticals’ acquisition of a gene therapy startup bolstered its ATTR pipeline, emphasizing long-term genetic solutions. Regulatory momentum remains strong, with the FDA’s accelerated approval of efgartigimod for ATTR neuropathy, highlighting a shift toward _targeted immunotherapies_. Meanwhile, patient demand is evolving, with a growing preference for non-invasive diagnostics and personalized treatment monitoring. Funding has surged, particularly in early-stage biotechs, as seen in a $50M Series B round for a company developing oral small-molecule stabilizers. Looking ahead, the industry is poised for disruption through _RNA interference technologies_ and expanded global trials, addressing unmet needs in both hereditary and wild-type ATTR populations.

Analyst Overview

Transthyretin Amyloidosis (ATTR) market outlook remains highly attractive due to unmet medical needs and advancements in targeted therapies. The market is driven by rising prevalence, improved diagnostic techniques, and robust R&D pipelines, positioning it for significant growth. However, competitive intensity is elevating as both established pharma giants and biotech innovators prioritize ATTR, leading to accelerated approvals and aggressive differentiation strategies.

Key Themes3 items

Long-term outlook is optimistic, with next-gen therapies (e.g., gene editing, RNAi) expected to redefine treatment paradigms by 2030.

Innovation landscape is dynamic, fueled by partnerships, novel mechanisms of action, and patient-centric trial designs.

Demand-supply balance remains skewed; while demand grows with patient identification, supply faces challenges from high treatment costs and manufacturing complexities.

Key risk factors include regulatory uncertainties, reimbursement barriers in emerging markets, and potential safety liabilities of experimental therapies. Sustained stakeholder collaboration and real-world evidence generation will be critical to mitigate these risks and ensure market attractiveness endures over the long term.

11 items

1. Executive Summary

2. Transthyretin Amyloidosis (ATTR) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transthyretin Amyloidosis (ATTR) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transthyretin Amyloidosis (ATTR) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.1.3. Diagnostic Centers

6.2. Global Transthyretin Amyloidosis (ATTR) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hereditary ATTR (HATTR)

6.2.2. Wild-Type (WT) ATTR

6.3. Global Transthyretin Amyloidosis (ATTR) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transthyretin Amyloidosis (ATTR) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transthyretin Amyloidosis (ATTR) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transthyretin Amyloidosis (ATTR) Market Competition by Key Manufacturers

8.1. Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transthyretin Amyloidosis (ATTR): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alnylam Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ionis Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Corino Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Proclara Bioscience

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Arcturus Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transthyretin Amyloidosis (ATTR) Market

Figure 4: Global Transthyretin Amyloidosis (ATTR) Market: Drivers

Figure 5: Global Transthyretin Amyloidosis (ATTR) Market: Challenges

Figure 6: Global Transthyretin Amyloidosis (ATTR) Market: Trends

Figure 7: Global Transthyretin Amyloidosis (ATTR) Market: Opportunity

Figure 8: Global Transthyretin Amyloidosis (ATTR) Market: Restraint

Figure 9: Global Transthyretin Amyloidosis (ATTR) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transthyretin Amyloidosis (ATTR) Market Value (USD Million) By Region

Figure 15: Global Transthyretin Amyloidosis (ATTR) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transthyretin Amyloidosis (ATTR) Market Value (USD Million) By Region

Figure 23: Global Transthyretin Amyloidosis (ATTR) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transthyretin Amyloidosis (ATTR) Market Value (USD Million) By Region

Table 10: Global Transthyretin Amyloidosis (ATTR) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transthyretin Amyloidosis (ATTR) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transthyretin Amyloidosis (ATTR) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transthyretin Amyloidosis (ATTR) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 33: Alnylam Pharmaceuticals. Products Portfolio

Table 34: Ionis Pharmaceuticals Basic Information And Sales Area

Table 35: Ionis Pharmaceuticals. Products Portfolio

Table 36: Corino Therapeutics Basic Information And Sales Area

Table 37: Corino Therapeutics. Products Portfolio

Table 38: Proclara Bioscience Basic Information And Sales Area

Table 39: Proclara Bioscience. Products Portfolio

Table 40: Arcturus Therapeutics Basic Information And Sales Area

Table 41: Arcturus Therapeutics. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Transthyretin Amyloidosis (ATTR) Market Value (USD Million) By Region

Table 47: Global Transthyretin Amyloidosis (ATTR) Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Transthyretin Amyloidosis (ATTR) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Alnylam Pharmaceuticals; Ionis Pharmaceuticals; Corino Therapeutics; Proclara Bioscience; Arcturus Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options